Cargando…

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia

Atypical chronic myeloid leukemia (aCML) is a BCR-ABL1-negative clonal disorder, which belongs to the myelodysplastic/myeloproliferative group. This disease is characterized by recurrent somatic mutations in SETBP1, ASXL1 and ETNK1 genes, as well as high genetic heterogeneity, thus posing a great th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fontana, Diletta, Ramazzotti, Daniele, Aroldi, Andrea, Redaelli, Sara, Magistroni, Vera, Pirola, Alessandra, Niro, Antonio, Massimino, Luca, Mastini, Cristina, Brambilla, Virginia, Bombelli, Silvia, Bungaro, Silvia, Morotti, Alessandro, Rea, Delphine, Stagno, Fabio, Martino, Bruno, Campiotti, Leonardo, Caocci, Giovanni, Usala, Emilio, Merli, Michele, Onida, Francesco, Bregni, Marco, Elli, Elena Maria, Fumagalli, Monica, Ciceri, Fabio, Perego, Roberto A., Pagni, Fabio, Mologni, Luca, Piazza, Rocco, Gambacorti-Passerini, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655091/ https://www.ncbi.nlm.nih.gov/pubmed/33196013 http://dx.doi.org/10.1097/HS9.0000000000000497

Ejemplares similares

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub
por: Piazza, Rocco, et al.
Publicado: (2018)

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
por: Mologni, Luca, et al.
Publicado: (2017)

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma
por: Arosio, Giulia, et al.
Publicado: (2021)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
por: Ceccon, Monica, et al.
Publicado: (2018)

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Rocco, Piazza, et al.
Publicado: (2017)

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Piazza, Rocco, et al.
Publicado: (2017)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
por: Magistroni, Vera, et al.
Publicado: (2019)

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
por: Aroldi, Andrea, et al.
Publicado: (2023)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery
por: Piazza, Rocco, et al.
Publicado: (2012)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
por: Fontana, Diletta, et al.
Publicado: (2023)

ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
por: Magistroni, Vera, et al.
Publicado: (2011)

Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft
por: Ciceri, Fabio, et al.
Publicado: (2011)

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
por: Bregni, Marco, et al.
Publicado: (2011)

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
por: Sharma, Geeta Geeta, et al.
Publicado: (2018)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2013)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2014)

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

P1056: NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES
por: Sangiorgio, Valentina, et al.
Publicado: (2023)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data
por: Piazza, Rocco, et al.
Publicado: (2013)

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)

Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review
por: Fontana, Diletta, et al.
Publicado: (2023)

VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples
por: Ramazzotti, Daniele, et al.
Publicado: (2021)

Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition
por: Nucera, Silvia, et al.
Publicado: (2020)

Whole brain delivery of an instability-prone Mecp2 transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome
por: Luoni, Mirko, et al.
Publicado: (2020)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

Demanding Diagnosis of Splenic Angiosarcoma as Cause of Delayed Treatment of Spontaneous Splenic Rupture: A Case Report and Literature Review
por: Coppola, Sara, et al.
Publicado: (2017)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_302tfgn18vbgqquig6lemjcr4r